Primary brain tumours in adults

[1]  Z. Ram,et al.  Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.

[2]  D. Correa,et al.  Delayed neurotoxicity in primary central nervous system lymphoma. , 2005, Archives of neurology.

[3]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[4]  H. Duffau.  Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity , 2005, The Lancet Neurology.

[5]  H. Karnath,et al.  NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report , 2005, Annals of neurology.

[6]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[7]  F. Jolesz,et al.  Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance , 2005, Cancer.

[8]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[9]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[10]  P. Dirks,et al.  Cancer stem cells in nervous system tumors , 2004, Oncogene.

[11]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Laurent Capelle,et al.  Preferential brain locations of low‐grade gliomas , 2004, Cancer.

[13]  E. Bruera,et al.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Hoang-Xuan,et al.  Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Hartmann,et al.  Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy , 2003, Neuroscience Letters.

[17]  Z. Ram,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[18]  Laurent Capelle,et al.  Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.

[19]  T. Batchelor,et al.  Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Tronnier,et al.  Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging , 2003, Neuroscience Letters.

[21]  B. Scheithauer,et al.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Janet E Olson,et al.  The continuing increase in the incidence of primary central nervous system non‐Hodgkin lymphoma , 2002, Cancer.

[23]  J. Gurney,et al.  Decreasing incidence rates of primary central nervous system lymphoma , 2002, Cancer.

[24]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[27]  L. Deangelis,et al.  Long-term survival in primary CNS lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Karim,et al.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. , 1996, International journal of radiation oncology, biology, physics.

[29]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[31]  L. Deangelis,et al.  Combined modality therapy for primary CNS lymphoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.